Clinical Trial Update: Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is investigating intrathecal administration of a PD-1/CTLA-4 bispecific antibody with pemetrexed for leptomeningeal metastasis; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis

Drugs mentioned

• PD-1/CTLA-4 bispecific antibody
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Leptomeningeal Metastasis | Phase 1, Phase 2 | Status: RECRUITING